BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36585521)

  • 1. High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.
    Aid Z; Robert E; Lopez CK; Bourgoin M; Boudia F; Le Mene M; Riviere J; Baille M; Benbarche S; Renou L; Fagnan A; Thirant C; Federici L; Touchard L; Lecluse Y; Jetten A; Geoerger B; Lapillonne H; Solary E; Gaudry M; Meshinchi S; Pflumio F; Auberger P; Lobry C; Petit A; Jacquel A; Mercher T
    Leukemia; 2023 Mar; 37(3):571-579. PubMed ID: 36585521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite functions in cell differentiation.
    Zhang YF; Wang XL; Xu CH; Liu N; Zhang L; Zhang YM; Xie YY; Zhang YL; Huang QH; Wang L; Chen Z; Chen SJ; Roeder RG; Shen S; Xue K; Sun XJ
    Front Cell Dev Biol; 2022; 10():992714. PubMed ID: 36158200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.
    Thirant C; Ignacimouttou C; Lopez CK; Diop M; Le Mouël L; Thiollier C; Siret A; Dessen P; Aid Z; Rivière J; Rameau P; Lefebvre C; Khaled M; Leverger G; Ballerini P; Petit A; Raslova H; Carmichael CL; Kile BT; Soler E; Crispino JD; Wichmann C; Pflumio F; Schwaller J; Vainchenker W; Lobry C; Droin N; Bernard OA; Malinge S; Mercher T
    Cancer Cell; 2017 Mar; 31(3):452-465. PubMed ID: 28292442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia.
    Thirant C; Lopez C; Malinge S; Mercher T
    Mol Cell Oncol; 2017; 4(6):e1345351. PubMed ID: 29209645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax.
    Neault M; Lebert-Ghali CÉ; Fournier M; Capdevielle C; Garfinkle EAR; Obermayer A; Cotton A; Boulay K; Sawchyn C; St-Amand S; Nguyen KH; Assaf B; Mercier FE; Delisle JS; Drobetsky EA; Hulea L; Shaw TI; Zuber J; Gruber TA; Melichar HJ; Mallette FA
    Cell Rep; 2023 Sep; 42(9):113084. PubMed ID: 37716355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia.
    Benbarche S; Lopez CK; Salataj E; Aid Z; Thirant C; Laiguillon MC; Lecourt S; Belloucif Y; Vaganay C; Antonini M; Hu J; da Silva Babinet A; Ndiaye-Lobry D; Pardieu B; Petit A; Puissant A; Chaumeil J; Mercher T; Lobry C
    Sci Adv; 2022 Feb; 8(6):eabg9455. PubMed ID: 35138899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.
    Xiang Z; Luo H; Payton JE; Cain J; Ley TJ; Opferman JT; Tomasson MH
    J Clin Invest; 2010 Jun; 120(6):2109-18. PubMed ID: 20484815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.
    Lopez CK; Noguera E; Stavropoulou V; Robert E; Aid Z; Ballerini P; Bilhou-Nabera C; Lapillonne H; Boudia F; Thirant C; Fagnan A; Arcangeli ML; Kinston SJ; Diop M; Job B; Lecluse Y; Brunet E; Babin L; Villeval JL; Delabesse E; Peters AHFM; Vainchenker W; Gaudry M; Masetti R; Locatelli F; Malinge S; Nerlov C; Droin N; Lobry C; Godin I; Bernard OA; Göttgens B; Petit A; Pflumio F; Schwaller J; Mercher T
    Cancer Discov; 2019 Dec; 9(12):1736-1753. PubMed ID: 31662298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ETO2-GLIS2: A Chimeric Transcription Factor Drives Leukemogenesis through a Neomorphic Transcription Network.
    Wheat JC; Steidl U
    Cancer Cell; 2017 Mar; 31(3):307-308. PubMed ID: 28292433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.
    Gress V; Roussy M; Boulianne L; Bilodeau M; Cardin S; El-Hachem N; Lisi V; Khakipoor B; Rouette A; Farah A; Théret L; Aubert L; Fatima F; Audemard É; Thibault P; Bonneil É; Chagraoui J; Laramée L; Gendron P; Jouan L; Jammali S; Paré B; Simpson SM; Tran TH; Duval M; Teira P; Bittencourt H; Santiago R; Barabé F; Sauvageau G; Smith MA; Hébert J; Roux PP; Gruber TA; Lavallée VP; Wilhelm BT; Cellot S
    Blood Adv; 2024 Jan; 8(1):112-129. PubMed ID: 37729615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
    Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
    Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Transcriptome Profiling of Cryptic
    Smith JL; Ries RE; Hylkema T; Alonzo TA; Gerbing RB; Santaguida MT; Eidenschink Brodersen L; Pardo L; Cummings CL; Loeb KR; Le Q; Imren S; Leonti AR; Gamis AS; Aplenc R; Kolb EA; Farrar JE; Triche TJ; Nguyen C; Meerzaman D; Loken MR; Oehler VG; Bolouri H; Meshinchi S
    Clin Cancer Res; 2020 Feb; 26(3):726-737. PubMed ID: 31719049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
    Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
    Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
    Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
    Masetti R; Bertuccio SN; Astolfi A; Chiarini F; Lonetti A; Indio V; De Luca M; Bandini J; Serravalle S; Franzoni M; Pigazzi M; Martelli AM; Basso G; Locatelli F; Pession A
    J Hematol Oncol; 2017 Jan; 10(1):26. PubMed ID: 28109323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis.
    Okamoto T; Coultas L; Metcalf D; van Delft MF; Glaser SP; Takiguchi M; Strasser A; Bouillet P; Adams JM; Huang DC
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):261-6. PubMed ID: 24363325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2.
    Obexer P; Hagenbuchner J; Rupp M; Salvador C; Holzner M; Deutsch M; Porto V; Kofler R; Unterkircher T; Ausserlechner MJ
    J Biol Chem; 2009 Nov; 284(45):30933-40. PubMed ID: 19737931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.